Endocrine complications of new anticancer therapies

[1] Abdulrahman R.M., Verloop H., Hoftijzer H., Verburg E., Hovens G.C., Corssmit E.P., Reiners C., Gelderblom H., Pereira A.M., Kapiteijn E., Romijn J.A., Visser T.J., Smit J.W.: Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J. Clin. Endocrinol. Metab., 2010; 95: 3758–3762 AbdulrahmanR.M. VerloopH. HoftijzerH. VerburgE. HovensG.C. CorssmitE.P. ReinersC. GelderblomH. PereiraA.M. KapiteijnE. RomijnJ.A. VisserT.J. SmitJ.W. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination J. Clin. Endocrinol. Metab. 2010 95 3758 3762 10.1210/jc.2009-250720484486 Search in Google Scholar

[2] Angell T.E.: Thyroiditis while receiving programmed death ligand 1 (PD-L1) inhibitor therapy for nonthyroid cancers is associated with improved overall survival. Clin. Thyroidol., 2020; 32: 65–68 AngellT.E. Thyroiditis while receiving programmed death ligand 1 (PD-L1) inhibitor therapy for nonthyroid cancers is associated with improved overall survival Clin. Thyroidol. 2020 32 65 68 10.1089/ct.2020;32.65-68 Search in Google Scholar

[3] Arima H., Iwama S., Inaba H., Ariyasu H., Makita N., Otsuki M., Kageyama K., Imagawa A., Akamizu T.: Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr. J., 2019; 66: 581–586 ArimaH. IwamaS. InabaH. AriyasuH. MakitaN. OtsukiM. KageyamaK. ImagawaA. AkamizuT. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society Endocr. J. 2019 66 581 586 10.1507/endocrj.EJ19-0163 Search in Google Scholar

[4] Baldazzi V., Tassi R., Lapini A., Lunghi A., Garofoli E., Caruso S., Carini M., Mazzanti R.: Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis. Cancer, 2012; 118: 3165–3172 BaldazziV. TassiR. LapiniA. LunghiA. GarofoliE. CarusoS. CariniM. MazzantiR. Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis Cancer 2012 118 3165 3172 10.1002/cncr.26435 Search in Google Scholar

[5] Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S., Min L., Krop I.E., Tolaney S.M.: Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol., 2018; 4: 173–182 Barroso-SousaR. BarryW.T. Garrido-CastroA.C. HodiF.S. MinL. KropI.E. TolaneyS.M. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis JAMA Oncol. 2018 4 173 182 10.1001/jamaoncol.2017.3064 Search in Google Scholar

[6] Bjornsti M.A., Houghton P.J: The TOR pathway: A target for cancer therapy. Nat. Rev. Cancer, 2004; 4: 335–348 BjornstiM.A. HoughtonP.J. The TOR pathway: A target for cancer therapy Nat. Rev. Cancer 2004 4 335 348 10.1038/nrc1362 Search in Google Scholar

[7] Blagosklonny M.V.: Fasting and rapamycin: Diabetes versus benevolent glucose intolerance. Cell Death Dis., 2019; 10: 607 BlagosklonnyM.V. Fasting and rapamycin: Diabetes versus benevolent glucose intolerance Cell Death Dis. 2019 10 607 10.1038/s41419-019-1822-8 Search in Google Scholar

[8] Blagosklonny M.V.: Rapamycin for longevity: Opinion article. Aging, 2019; 11: 8048–8067 BlagosklonnyM.V. Rapamycin for longevity: Opinion article Aging 2019 11 8048 8067 10.18632/aging.102355 Search in Google Scholar

[9] Brancatella A., Viola N., Brogioni S., Montanelli L., Sardella C., Vitti P., Marcocci C., Lupi I., Latrofa F.: Graves’ disease induced by immune checkpoint inhibitors: A case report and review of the literature. Eur. Thyroid J., 2019; 8: 192–195 BrancatellaA. ViolaN. BrogioniS. MontanelliL. SardellaC. VittiP. MarcocciC. LupiI. LatrofaF. Graves’ disease induced by immune checkpoint inhibitors: A case report and review of the literature Eur. Thyroid J. 2019 8 192 195 10.1159/000501824 Search in Google Scholar

[10] Braun D., Kim T.D., le Coutre P., Köhrle J., Hershman J.M., Schweizer U.: Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J. Clin. Endocrinol. Metab., 2012; 97: E100–E105 BraunD. KimT.D. le CoutreP. KöhrleJ. HershmanJ.M. SchweizerU. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport J. Clin. Endocrinol. Metab. 2012 97 E100 E105 10.1210/jc.2011-1837 Search in Google Scholar

[11] Buffier P., Bouillet B., Smati S., Archambeaud F., Cariou B., Verges B.: Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors. Ann. Endocrinol., 2018; 79: 574–582 BuffierP. BouilletB. SmatiS. ArchambeaudF. CariouB. VergesB. Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors Ann. Endocrinol. 2018 79 574 582 10.1016/j.ando.2018.07.01130174137 Search in Google Scholar

[12] Castinetti F., Albarel F., Archambeaud F., Bertherat J., Bouillet B., Buffier P., Briet C., Cariou B., Caron P., Chabre O., Chanson P., Cortet C., Do Cao C., Drui D., Haissaguerre M. i wsp.: Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions. Ann. Endocrinol., 2018; 79: 591–595 CastinettiF. AlbarelF. ArchambeaudF. BertheratJ. BouilletB. BuffierP. BrietC. CariouB. CaronP. ChabreO. ChansonP. CortetC. Do CaoC. DruiD. HaissaguerreM. i wsp. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions Ann. Endocrinol. 2018 79 591 595 10.1016/j.ando.2018.07.00530056975 Search in Google Scholar

[13] Castinetti F., Borson-Chazot F.: Introduction to expert opinion on endocrine complications of new anticancer therapies. Ann. Endocrinol., 2018; 79: 535–538 CastinettiF. Borson-ChazotF. Introduction to expert opinion on endocrine complications of new anticancer therapies Ann. Endocrinol. 2018 79 535 538 10.1016/j.ando.2018.07.00130056976 Search in Google Scholar

[14] Clemons J., Gao D., Naam M., Breaker K., Garfield D., Flaig T.W.: Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin. Genitourin. Cancer, 2012; 10: 225–231 ClemonsJ. GaoD. NaamM. BreakerK. GarfieldD. FlaigT.W. Thyroid dysfunction in patients treated with sunitinib or sorafenib Clin. Genitourin. Cancer 2012 10 225 231 10.1016/j.clgc.2012.08.002351190823017335 Search in Google Scholar

[15] Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F.: Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab., 2013; 98: 1361–1375 CorselloS.M. BarnabeiA. MarchettiP. De VecchisL. SalvatoriR. TorinoF. Endocrine side effects induced by immune checkpoint inhibitors J. Clin. Endocrinol. Metab. 2013 98 1361 1375 10.1210/jc.2012-407523471977 Search in Google Scholar

[16] Darvin P., Toor S.M., Nair V.S, Elkord E.: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med., 2018; 50: 1–11 DarvinP. ToorS.M. NairV.S. ElkordE. Immune checkpoint inhibitors: Recent progress and potential biomarkers Exp. Mol. Med. 2018 50 1 11 10.1038/s12276-018-0191-1629289030546008 Search in Google Scholar

[17] de Filette J., Andreescu C.E., Cools F., Bravenboer B., Velkeniers B.: A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res., 2019; 51: 145–156 de FiletteJ. AndreescuC.E. CoolsF. BravenboerB. VelkeniersB. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors Horm. Metab. Res. 2019 51 145 156 10.1055/a-0843-336630861560 Search in Google Scholar

[18] de Filette J.M., Pen J.J., Decoster L., Vissers T., Bravenboer B., Van der Auwera B.J., Gorus F.K., Roep B.O., Aspeslagh S., Neyns B., Velkeniers B., Kharagjitsingh A.V.: Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review. Eur. J. Endocrinol., 2019; 181: 363–374 de FiletteJ.M. PenJ.J. DecosterL. VissersT. BravenboerB. Van der AuweraB.J. GorusF.K. RoepB.O. AspeslaghS. NeynsB. VelkeniersB. KharagjitsinghA.V. Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review Eur. J. Endocrinol. 2019 181 363 374 10.1530/EJE-19-0291670954531330498 Search in Google Scholar

[19] Deligiorgi M.V., Panayiotidis M.I., Trafalis D.T.: Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. Int. Immunopharmacol., 2019; 77: 105942 DeligiorgiM.V. PanayiotidisM.I. TrafalisD.T. Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions Int. Immunopharmacol. 2019 77 105942 10.1016/j.intimp.2019.10594231699669 Search in Google Scholar

[20] Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B. i wsp.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002; 347: 472–480 DemetriG.D. von MehrenM. BlankeC.D. Van den AbbeeleA.D. EisenbergB. RobertsP.J. HeinrichM.C. TuvesonD.A. SingerS. JanicekM. FletcherJ.A. SilvermanS.G. SilbermanS.L. CapdevilleR. KieseB. i wsp. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 2002 347 472 480 10.1056/NEJMoa02046112181401 Search in Google Scholar

[21] Feldt S., Schüssel K., Quinzler R., Franzmann A., Czeche S., Ludwig W.D., Schulz M.: Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study. Eur. J. Cancer, 2012; 48: 974–981 FeldtS. SchüsselK. QuinzlerR. FranzmannA. CzecheS. LudwigW.D. SchulzM. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study Eur. J. Cancer 2012 48 974 981 10.1016/j.ejca.2012.01.03622382202 Search in Google Scholar

[22] Fountas A., Diamantopoulos L.N., Tsatsoulis A.: Tyrosine kinase inhibitors and diabetes: A novel treatment paradigm? Trends Endocrinol. Metab., 2015; 26: 643–656 FountasA. DiamantopoulosL.N. TsatsoulisA. Tyrosine kinase inhibitors and diabetes: A novel treatment paradigm? Trends Endocrinol. Metab. 2015 26 643 656 10.1016/j.tem.2015.09.00326492832 Search in Google Scholar

[23] Fraenkel M., Ketzinel-Gilad M., Ariav Y., Pappo O., Karaca M., Castel J., Berthault M.F., Magnan C., Cerasi E., Kaiser N., Leibowitz G.: mTOR inhibition by rapamycin prevents – β cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes, 2008; 57: 945–957 FraenkelM. Ketzinel-GiladM. AriavY. PappoO. KaracaM. CastelJ. BerthaultM.F. MagnanC. CerasiE. KaiserN. LeibowitzG. mTOR inhibition by rapamycin prevents – β cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes Diabetes 2008 57 945 957 10.2337/db07-092218174523 Search in Google Scholar

[24] Green M.R., Newton M.D., Fancher K.M.: Off-target effects of BCR-ABL and JAK2 inhibitors. Am. J. Clin. Oncol., 2016; 39: 76–84 GreenM.R. NewtonM.D. FancherK.M. Off-target effects of BCR-ABL and JAK2 inhibitors Am. J. Clin. Oncol. 2016 39 76 84 10.1097/COC.000000000000002324351780 Search in Google Scholar

[25] Guertin D.A, Sabatini D.M.: Defining the role of mTOR in cancer. Cancer Cell, 2007; 12: 9–22 GuertinD.A. SabatiniD.M. Defining the role of mTOR in cancer Cancer Cell 2007 12 9 22 10.1016/j.ccr.2007.05.00817613433 Search in Google Scholar

[26] Gutierrez C., McEvoy C., Munshi L., Stephens R.S., Detsky M.E., Nates J.L., Pastores S.M.: Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit. Care Med., 2020; 48: 10–21 GutierrezC. McEvoyC. MunshiL. StephensR.S. DetskyM.E. NatesJ.L. PastoresS.M. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer Crit. Care Med. 2020 48 10 21 10.1097/CCM.0000000000004087750509231725440 Search in Google Scholar

[27] Hay N., Sonenberg N.: Upstream and downstream of mTOR. Genes Dev., 2004; 18: 1926–1945 HayN. SonenbergN. Upstream and downstream of mTOR Genes Dev. 2004 18 1926 1945 10.1101/gad.121270415314020 Search in Google Scholar

[28] Iyer P.C, Cabanillas M.E., Waguespack S.G., Hu M.I., Thosani S., Lavis V.R., Busaidy N.L., Subudhi S.K., Diab A., Dadu R.: Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid, 2018; 28: 1243–1251 IyerP.C. CabanillasM.E. WaguespackS.G. HuM.I. ThosaniS. LavisV.R. BusaidyN.L. SubudhiS.K. DiabA. DaduR. Immune-related thyroiditis with immune checkpoint inhibitors Thyroid 2018 28 1243 1251 10.1089/thy.2018.0116615735930132401 Search in Google Scholar

[29] Kappers M.H.W., van Esch J.H.M., Smedts F.M.M., de Krijger R.R., Eechoute K., Mathijssen R.H.J., Sleijfer S., Leijten F., Danser A.H.J., van den Meiracker A.H., Visser T.J.: Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J. Clin. Endocrinol. Metab., 2011; 96: 3087–3094 KappersM.H.W. van EschJ.H.M. SmedtsF.M.M. de KrijgerR.R. EechouteK. MathijssenR.H.J. SleijferS. LeijtenF. DanserA.H.J. van den MeirackerA.H. VisserT.J. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression J. Clin. Endocrinol. Metab. 2011 96 3087 3094 10.1210/jc.2011-117221816788 Search in Google Scholar

[30] Kassi E., Angelousi A., Asonitis N., Diamantopoulos P., Anastasopoulou A., Papaxoinis G., Kokkinos M., Giovanopoulos I., Kyriakakis G., Petychaki F., Savelli A., Benopoulou O., Gogas H.: Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Med., 2019; 8: 6585–6594 KassiE. AngelousiA. AsonitisN. DiamantopoulosP. AnastasopoulouA. PapaxoinisG. KokkinosM. GiovanopoulosI. KyriakakisG. PetychakiF. SavelliA. BenopoulouO. GogasH. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma Cancer Med. 2019 8 6585 6594 10.1002/cam4.2533682597431518074 Search in Google Scholar

[31] Kitajima K., Takahashi S., Maeda T., Yoshikawa T., Ohno Y., Fujii M., Miyake H., Fujisawa M., Sugimura K.: Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function. Eur. J. Radiol., 2012; 81: 2060–2065 KitajimaK. TakahashiS. MaedaT. YoshikawaT. OhnoY. FujiiM. MiyakeH. FujisawaM. SugimuraK. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function Eur. J. Radiol. 2012 81 2060 2065 10.1016/j.ejrad.2011.06.03521724350 Search in Google Scholar

[32] Kluczyński Ł., Gilis-Januszewska A., Rogoziński D., Pantofliński J., Hubalewska-Dydejczyk A.: Hypophysitis-new insights into diagnosis and treatment. Endokrynol. Pol., 2019; 70: 260–269 KluczyńskiŁ. Gilis-JanuszewskaA. RogozińskiD. PantoflińskiJ. Hubalewska-DydejczykA. Hypophysitis-new insights into diagnosis and treatment Endokrynol. Pol. 2019 70 260 269 10.5603/EP.a2019.001531290557 Search in Google Scholar

[33] Kobayashi T., Iwama S., Yasuda Y., Okada N., Tsunekawa T., Onoue T., Takagi H., Hagiwara D., Ito Y., Morishita Y., Goto M., Suga H., Banno R., Yokota K. i wsp.: Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study. J. Endocr. Soc., 2018; 2: 241–251 KobayashiT. IwamaS. YasudaY. OkadaN. TsunekawaT. OnoueT. TakagiH. HagiwaraD. ItoY. MorishitaY. GotoM. SugaH. BannoR. YokotaK. i wsp. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study J. Endocr. Soc. 2018 2 241 251 10.1210/js.2017-00432583652929600292 Search in Google Scholar

[34] Kotwal A., Haddox C., Block M., Kudva Y.C.: Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes. BMJ Open Diab. Res. Care, 2019; 7: e000591 KotwalA. HaddoxC. BlockM. KudvaY.C. Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes BMJ Open Diab. Res. Care 2019 7 e000591 10.1136/bmjdrc-2018-000591639881330899528 Search in Google Scholar

[35] Kraig E., Linehan L.A., Liang H., Romo T.Q., Liu Q., Wu Y., Benavides A.D., Curiel T.J., Javors M.A., Musi N., Chiodo L., Koek W., Gelfond J.A.L., Kellogg D.L.Jr.: A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp. Gerontol., 2018; 105: 53–69 KraigE. LinehanL.A. LiangH. RomoT.Q. LiuQ. WuY. BenavidesA.D. CurielT.J. JavorsM.A. MusiN. ChiodoL. KoekW. GelfondJ.A.L. KelloggD.L.Jr. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects Exp. Gerontol. 2018 105 53 69 10.1016/j.exger.2017.12.026586916629408453 Search in Google Scholar

[36] Krajewska J., Paliczka-Cieslik E., Jarzab B.: Managing tyrosine kinase inhibitors side effects in thyroid cancer. Expert Rev. Endocrinol. Metab., 2017; 12: 117–127 KrajewskaJ. Paliczka-CieslikE. JarzabB. Managing tyrosine kinase inhibitors side effects in thyroid cancer Expert Rev. Endocrinol. Metab. 2017 12 117 127 10.1080/17446651.2017.130052630063430 Search in Google Scholar

[37] Król A., Gawlik T., Jarząb B.: Endocrine complications of cancer immunotherapy. Endokrynol. Pol., 2018; 69: 722–733 KrólA. GawlikT. JarząbB. Endocrine complications of cancer immunotherapy Endokrynol. Pol. 2018 69 722 733 10.5603/EP.a2018.007330618030 Search in Google Scholar

[38] Kroschinsky F., Stölzel F., von Bonin S., Beutel G., Kochanek M., Kiehl M., Schellongowski P., Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group: New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management. Crit. Care, 2017; 21: 89 KroschinskyF. StölzelF. von BoninS. BeutelG. KochanekM. KiehlM. SchellongowskiP. Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management Crit. Care 2017 21 89 10.1186/s13054-017-1678-1539160828407743 Search in Google Scholar

[39] Kyi C., Postow M.A.: Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett., 2014; 588: 368–376 KyiC. PostowM.A. Checkpoint blocking antibodies in cancer immunotherapy FEBS Lett. 2014 588 368 376 10.1016/j.febslet.2013.10.01524161671 Search in Google Scholar

[40] Lanzolla G., Coppelli A., Cosottini M., Del Prato S., Marcocci C., Lupi I.: Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome. J. Endocr. Soc., 2019; 3: 496–503 LanzollaG. CoppelliA. CosottiniM. Del PratoS. MarcocciC. LupiI. Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome J. Endocr. Soc. 2019 3 496 503 10.1210/js.2018-00366636462430746508 Search in Google Scholar

[41] Li J., Wang M., Zhang B., Wu X., Lin T.L., Liu X.F., Zhou Y., Zhang X.H., Xu H., Shen L.J., Zou J., Lu P., Zhang D., Gu W.J., Zhang M.X., Pan J., Cao H., Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association: Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World J. Gastroenterol., 2018; 24: 5189–5202 LiJ. WangM. ZhangB. WuX. LinT.L. LiuX.F. ZhouY. ZhangX.H. XuH. ShenL.J. ZouJ. LuP. ZhangD. GuW.J. ZhangM.X. PanJ. CaoH. Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors World J. Gastroenterol. 2018 24 5189 5202 10.3748/wjg.v24.i46.5189629584030581268 Search in Google Scholar

[42] Liu S., Kurzrock R.: Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat. Rev., 2014; 40: 883–891 LiuS. KurzrockR. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms Cancer Treat. Rev. 2014 40 883 891 10.1016/j.ctrv.2014.05.00324867380 Search in Google Scholar

[43] Lu J., Li L., Lan Y., Liang Y., Meng H.: Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Med., 2019; 8: 7503–7515 LuJ. LiL. LanY. LiangY. MengH. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis Cancer Med. 2019 8 7503 7515 10.1002/cam4.2661691206231679184 Search in Google Scholar

[44] Lupu J., Pages C., Laly P., Delyon J., Laloi M., Petit A., Basset-Seguin N., Oueslati I., Zagdanski A.M., Young J., Bouche C., Lebbé C., Gautier J.F.: Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. Melanoma Res., 2017; 27: 649–652 LupuJ. PagesC. LalyP. DelyonJ. LaloiM. PetitA. Basset-SeguinN. OueslatiI. ZagdanskiA.M. YoungJ. BoucheC. LebbéC. GautierJ.F. Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination Melanoma Res. 2017 27 649 652 10.1097/CMR.000000000000040529036015 Search in Google Scholar

[45] Makita N., Iiri T.: Tyrosine kinase inhibitor-induced thyroid disorders: A review and hypothesis. Thyroid, 2013; 23: 151–159 MakitaN. IiriT. Tyrosine kinase inhibitor-induced thyroid disorders: A review and hypothesis Thyroid 2013 23 151 159 10.1089/thy.2012.045623398161 Search in Google Scholar

[46] Makita N., Miyakawa M., Fujita T., Iiri T.: Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid, 2010; 20: 323–326 MakitaN. MiyakawaM. FujitaT. IiriT. Sunitinib induces hypothyroidism with a markedly reduced vascularity Thyroid 2010 20 323 326 10.1089/thy.2009.041420187785 Search in Google Scholar

[47] Mannavola D., Coco P., Vannucchi G., Bertuelli R., Carletto M., Casali P.G., Beck-Peccoz P., Fugazzola L.: A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J. Clin. Endocrinol. Metab., 2007; 92: 3531–3534 MannavolaD. CocoP. VannucchiG. BertuelliR. CarlettoM. CasaliP.G. Beck-PeccozP. FugazzolaL. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake J. Clin. Endocrinol. Metab. 2007 92 3531 3534 10.1210/jc.2007-058617595247 Search in Google Scholar

[48] Marcq E., Waele J.D., Audenaerde J.V., Lion E., Santermans E., Hens N., Pauwels P., van Meerbeeck J.P., Smits E.L.J.: Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. Oncotarget, 2017; 8: 89722–89735 MarcqE. WaeleJ.D. AudenaerdeJ.V. LionE. SantermansE. HensN. PauwelsP. van MeerbeeckJ.P. SmitsE.L.J. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients Oncotarget 2017 8 89722 89735 10.18632/oncotarget.21113568570429163783 Search in Google Scholar

[49] Martins F., de Oliveira M.A., Wang Q., Sonis S., Gallottini M., George S., Treister N.: A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol., 2013; 49: 293–298 MartinsF. de OliveiraM.A. WangQ. SonisS. GallottiniM. GeorgeS. TreisterN. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients Oral Oncol. 2013 49 293 298 10.1016/j.oraloncology.2012.11.00823312237 Search in Google Scholar

[50] Matrana M.R., Duran C., Shetty A., Xiao L., Atkinson B.J., Corn P., Pagliaro L.C., Millikan R.E., Charnsangave C., Jonasch E., Tannir N.M.: Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur. J. Cancer, 2013; 49: 3169–3175 MatranaM.R. DuranC. ShettyA. XiaoL. AtkinsonB.J. CornP. PagliaroL.C. MillikanR.E. CharnsangaveC. JonaschE. TannirN.M. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies Eur. J. Cancer 2013 49 3169 3175 10.1016/j.ejca.2013.06.003388215623810246 Search in Google Scholar

[51] Min L., Vaidya A., Becker C.: Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur. J. Endocrinol., 2011; 164: 303–307 MinL. VaidyaA. BeckerC. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy Eur. J. Endocrinol. 2011 164 303 307 10.1530/EJE-10-0833408062921088057 Search in Google Scholar

[52] Neumann D., Korzeniowska K., Jankowski J., Jabłecka A.: Kardiotoksyczność leczenia przeciwnowotworowego. Chor. Serca Naczyń, 2016; 13: 434–444 NeumannD. KorzeniowskaK. JankowskiJ. JabłeckaA. Kardiotoksyczność leczenia przeciwnowotworowego Chor. Serca Naczyń 2016 13 434 444 Search in Google Scholar

[53] Nurgali K., Jagoe R.T., Abalo R.: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front Pharmacol., 2018; 9: 245 NurgaliK. JagoeR.T. AbaloR. Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018 9 245 10.3389/978-2-88945-482-2 Search in Google Scholar

[54] Ohba K., Takayama T., Matsunaga H., Matsushita A., Sasaki S., Oki Y., Ozono S., Nakamura H.: Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid, 2013; 23: 443–448 OhbaK. TakayamaT. MatsunagaH. MatsushitaA. SasakiS. OkiY. OzonoS. NakamuraH. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib Thyroid 2013 23 443 448 10.1089/thy.2012.037823157669 Search in Google Scholar

[55] Pal S.K., Miller M.J., Agarwal N., Chang S.M., Chavez-MacGregor M., Cohen E., Cole S., Dale W., Magid Diefenbach C.S., Disis M.L., Dreicer R., Graham D.L., Henry N.L., Jones J., Keedy V. i wsp.: Clinical cancer advances 2019: Annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol., 2019; 37: 834–849 PalS.K. MillerM.J. AgarwalN. ChangS.M. Chavez-MacGregorM. CohenE. ColeS. DaleW. Magid DiefenbachC.S. DisisM.L. DreicerR. GrahamD.L. HenryN.L. JonesJ. KeedyV. i wsp. Clinical cancer advances 2019: Annual report on progress against cancer from the American Society of Clinical Oncology J. Clin. Oncol. 2019 37 834 849 10.1200/JCO.18.0203730702028 Search in Google Scholar

[56] Paul M.K., Mukhopadhyay A.K.: Tyrosine kinase – Role and significance in cancer. Int. J. Med. Sci., 2004; 1: 101–115 PaulM.K. MukhopadhyayA.K. Tyrosine kinase – Role and significance in cancer Int. J. Med. Sci. 2004 1 101 115 10.7150/ijms.1.101107471815912202 Search in Google Scholar

[57] Piranavan P., Li Y., Brown E., Kemp E.H., Trivedi N.: Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol. Metab., 2019; 104: 550–556 PiranavanP. LiY. BrownE. KempE.H. TrivediN. Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies J. Clin. Endocrinol. Metab. 2019 104 550 556 10.1210/jc.2018-0115130252069 Search in Google Scholar

[58] Płużański A., Piórek A.: Side effects of tyrosine kinase inhibitors — management guidelines. Oncol. Clin. Pract., 2016; 12: 113–118 PłużańskiA. PiórekA. Side effects of tyrosine kinase inhibitors — management guidelines Oncol. Clin. Pract. 2016 12 113 118 Search in Google Scholar

[59] Prete A., Salvatori R.: Hypophysitis. https://www.ncbi.nlm.nih.gov/books/NBK519842 (15.08.2018) PreteA. SalvatoriR. Hypophysitis https://www.ncbi.nlm.nih.gov/books/NBK519842 (15.08.2018) Search in Google Scholar

[60] Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., Reddy S., Dreicer R., Bukowski R.M.: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Nat. Cancer Inst., 2007; 99: 81–83 RiniB.I. TamaskarI. ShaheenP. SalasR. GarciaJ. WoodL. ReddyS. DreicerR. BukowskiR.M. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib J. Nat. Cancer Inst. 2007 99 81 83 10.1093/jnci/djk00817202116 Search in Google Scholar

[61] Sagiv O., Kandl T.J, Thakar S.D., Thuro B.A, Busaidy N.L., Cabanillas M., Jimenez C., Dadu R., Graham P.H., Debnam J.M., Esmaeli B.: Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast. Reconstr. Surg., 2019; 35: 50–52 SagivO. KandlT.J. ThakarS.D. ThuroB.A. BusaidyN.L. CabanillasM. JimenezC. DaduR. GrahamP.H. DebnamJ.M. EsmaeliB. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients Ophthalmic Plast. Reconstr. Surg. 2019 35 50 52 10.1097/IOP.000000000000116129927883 Search in Google Scholar

[62] Santoni M., Conti A., Massari F., Di Nunno V., Faloppi L., Galizia E., Morbiducci J., Piva F., Buti S., Iacovelli R., Ferretti B., Cimadamore A., Scarpelli M., Lopez-Beltran A., Cheng L., Battelli N., Montironi R.: Targeted therapy for solid tumors and risk of hypertension: A meta-analysis of 68077 patients from 93 phase III studies. Exp. Rev. Cardiovasc. Ther., 2019; 17: 917–927 SantoniM. ContiA. MassariF. Di NunnoV. FaloppiL. GaliziaE. MorbiducciJ. PivaF. ButiS. IacovelliR. FerrettiB. CimadamoreA. ScarpelliM. Lopez-BeltranA. ChengL. BattelliN. MontironiR. Targeted therapy for solid tumors and risk of hypertension: A meta-analysis of 68077 patients from 93 phase III studies Exp. Rev. Cardiovasc. Ther. 2019 17 917 927 10.1080/14779072.2019.170462631829045 Search in Google Scholar

[63] Shu M., Zai X., Zhang B., Wang R., Lin Z.: Hypothyroidism side effect in patients treated with sunitinib or sorafenib: Clinical and structural analyses. PLoS One, 2016; 11: e0147048 ShuM. ZaiX. ZhangB. WangR. LinZ. Hypothyroidism side effect in patients treated with sunitinib or sorafenib: Clinical and structural analyses PLoS One 2016 11 e0147048 10.1371/journal.pone.0147048471844826784451 Search in Google Scholar

[64] Sivendran S., Agarwal N., Gartrell B., Ying J., Boucher K.M., Choueiri T.K., Sonpavde G., Oh W.K., Galsky M.D.: Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat. Rev., 2014; 40: 190–196 SivendranS. AgarwalN. GartrellB. YingJ. BoucherK.M. ChoueiriT.K. SonpavdeG. OhW.K. GalskyM.D. Metabolic complications with the use of mTOR inhibitors for cancer therapy Cancer Treat. Rev. 2014 40 190 196 10.1016/j.ctrv.2013.04.005474448623684373 Search in Google Scholar

[65] Sobańska K., Szałek E., Kamińska A., Grześkowiak E.: Inhibitory kinaz tyrozynowych w terapii przeciwnowotworowej. Farm. Współ., 2011; 4: 185–190 SobańskaK. SzałekE. KamińskaA. GrześkowiakE. Inhibitory kinaz tyrozynowych w terapii przeciwnowotworowej Farm. Współ. 2011 4 185 190 Search in Google Scholar

[66] Sosa A., Lopez Cadena E., Simon Olive C., Karachaliou N., Rosell R.: Clinical assessment of immune-related adverse events. Ther. Adv. Med. Oncol., 2018; 10: 1758835918764628 SosaA. Lopez CadenaE. Simon OliveC. KarachaliouN. RosellR. Clinical assessment of immune-related adverse events Ther. Adv. Med. Oncol. 2018 10 1758835918764628 10.1177/1758835918764628588203929623110 Search in Google Scholar

[67] Tamaskar I., Bukowski R., Elson P., Ioachimescu A.G., Wood L., Dreicer R., Mekhail T., Garcia J., Rini B.I.: Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol., 2008; 19: 265–268 TamaskarI. BukowskiR. ElsonP. IoachimescuA.G. WoodL. DreicerR. MekhailT. GarciaJ. RiniB.I. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib Ann. Oncol. 2008 19 265 268 10.1093/annonc/mdm48317962201 Search in Google Scholar

[68] Tan M.H., Iyengar R., Mizokami-Stout K., Yentz S., MacEachern M.P., Shen L.Y., Redman B., Gianchandani R.: Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: A scoping review of case reports. Clin. Diabet. Endocrinol., 2019; 5: 1 TanM.H. IyengarR. Mizokami-StoutK. YentzS. MacEachernM.P. ShenL.Y. RedmanB. GianchandaniR. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: A scoping review of case reports Clin. Diabet. Endocrinol. 2019 5 1 10.1186/s40842-018-0073-4634325530693099 Search in Google Scholar

[69] Torino F., Barnabei A., Paragliola R.M., Marchetti P., Salvatori R., Corsello S.M.: Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur. J. Endocrinol., 2013; 169: R153–R164 TorinoF. BarnabeiA. ParagliolaR.M. MarchettiP. SalvatoriR. CorselloS.M. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses Eur. J. Endocrinol. 2013 169 R153 R164 10.1530/EJE-13-043424001893 Search in Google Scholar

[70] Verloop H., Smit J.W., Dekkers O.M.: Sorafenib therapy decreases the clearance of thyrotropin. Eur. J. Endocrinol., 2013; 168: 163–167 VerloopH. SmitJ.W. DekkersO.M. Sorafenib therapy decreases the clearance of thyrotropin Eur. J. Endocrinol. 2013 168 163 167 10.1530/EJE-12-082823125304 Search in Google Scholar

[71] Veroux M., Tallarita T., Corona D., Sinagra N., Giaquinta A., Zerbo D., Guerrieri C., D’Assoro A., Cimino S., Veroux P.: Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation. Clin. Dev. Immunol., 2013; 2013: 496974 VerouxM. TallaritaT. CoronaD. SinagraN. GiaquintaA. ZerboD. GuerrieriC. D’AssoroA. CiminoS. VerouxP. Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation Clin. Dev. Immunol. 2013 2013 496974 10.1155/2013/496974367152623762090 Search in Google Scholar

[72] Walko C.M., Aubert R.E., La-Beck N.M., Clore G., Herrera V., Kourlas H., Epstein R.S., McLeod H.L.: Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib. Oncologist, 2017; 22: 208–212 WalkoC.M. AubertR.E. La-BeckN.M. CloreG. HerreraV. KourlasH. EpsteinR.S. McLeodH.L. Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib Oncologist 2017 22 208 212 10.1634/theoncologist.2016-0233533071028167571 Search in Google Scholar

[73] Wang D.Y., Salem J.E., Cohen J.V., Chandra S., Menzer C., Ye F., Zhao S., Das S., Beckermann K.E., Ha L., Rathmell W.K., Ancell K.K., Balko J.M., Bowman C., Davis E.J. i wsp.: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol., 2018; 4: 1721–1728 WangD.Y. SalemJ.E. CohenJ.V. ChandraS. MenzerC. YeF. ZhaoS. DasS. BeckermannK.E. HaL. RathmellW.K. AncellK.K. BalkoJ.M. BowmanC. DavisE.J. i wsp. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis JAMA Oncol. 2018 4 1721 1728 10.1001/jamaoncol.2018.3923644071230242316 Search in Google Scholar

[74] Wong E., Rosen L.S., Mulay M., Vanvugt A., Dinolfo M., Tomoda C., Sugawara M., Hershman J.M.: Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid, 2007; 17: 351–355 WongE. RosenL.S. MulayM. VanvugtA. DinolfoM. TomodaC. SugawaraM. HershmanJ.M. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity Thyroid 2007 17 351 355 10.1089/thy.2006.030817465866 Search in Google Scholar

[75] Yajima K., Akise Y.: A case report of Graves’ disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient. Case Rep. Endocrinol., 2019; 2019: 2314032 YajimaK. AkiseY. A case report of Graves’ disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient Case Rep. Endocrinol. 2019 2019 2314032 10.1155/2019/2314032685423431772785 Search in Google Scholar

[76] Yang J.C., Reguart N., Barinoff J., Köhler J., Uttenreuther-Fischer M., Stammberger U., O’Brien D., Wolf J., Cohen E.E.: Diarrhea associated with afatinib: An oral ErbB family blocker. Expert Rev. Anticancer Ther., 2013; 13: 729–736 YangJ.C. ReguartN. BarinoffJ. KöhlerJ. Uttenreuther-FischerM. StammbergerU. O’BrienD. WolfJ. CohenE.E. Diarrhea associated with afatinib: An oral ErbB family blocker Expert Rev. Anticancer Ther. 2013 13 729 736 10.1586/era.13.3123506556 Search in Google Scholar

[77] Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J., Strauss J., Brownell I.: Anti-PD-L1 treatment induced central diabetes insipidus. J. Clin. Endocrinol. Metab., 2018; 103: 365–369 ZhaoC. TellaS.H. Del RiveroJ. KommalapatiA. EbenuwaI. GulleyJ. StraussJ. BrownellI. Anti-PD-L1 treatment induced central diabetes insipidus J. Clin. Endocrinol. Metab. 2018 103 365 369 10.1210/jc.2017-01905580082629220526 Search in Google Scholar